Daniel E. Casey | Psychiatrist.com

Article

Antipsychotic Drugs, Insulin Resistance, Hyperglycemia, and Diabetes Mellitus

Article

Antipsychotic-Induced Weight Gain: A Review of the Literature

Article

Clinical Trial Design Issues in Schizophrenic Research

Original Research

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

Article

Conclusions: Antipsychotic-Induced Weight Gain and Metabolic Abnormalities

Article

Dyslipidemia and Atypical Antipsychotic Drugs

Article

Effects of Clozapine Therapy in Schizophrenic Individuals at Risk for Tardive Dyskinesia

Article

Epidemiology of Cardiovascular Disease and Major Metabolic Risk Factors

Article

The Impact of Atypical Antipsychotics on Weight Gain

Article

Introduction. Antipsychotic Standard of Care: Redefining the Definition of Atypical Antipsychotics

Article

Introduction: Update on Tardive Dyskinesia

Commentary

Metabolic Effects of Treatment With Atypical Antipsychotics

Article

Monitoring Metabolic Side Effects

Article

Pathophysiology of Antipsychotic Drug-Induced Movement Disorders

Article

The Pharmacology of Weight Gain With Antipsychotics

Article

The Relationship of Pharmacology to Side Effects

Article

Schizophrenia, Metabolic Disorders, and Cardiovascular Disease

Article

Tardive Dyskinesia: Pathophysiology and Animal Models

Article

Treatment Recommendations for Psychiatrists

Article

Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis and the Predictive Value of Week 2 Early Response

This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard antidepressant therapy (ADT) in patients...